152 
reasons such pediatric formulation cannot 
be developed. 
‘‘(B) ADVERSE EVENT REPORTS.—An ap-
plicant or holder that, on or after the date of 
the enactment of the Best Pharmaceuticals for 
Children Act of 2007, agrees to the request for 
such studies shall provide the Secretary, at the 
same time as the submission of the reports of 
such studies, with all postmarket adverse event 
reports regarding the drug that is the subject 
of such studies and are available prior to sub-
mission of such reports. 
‘‘(3) MEETING THE STUDIES REQUIREMENT.— 
Not later than 180 days after the submission of the 
reports of the studies, the Secretary shall accept or 
reject such reports and so notify the sponsor or 
holder. The Secretary’s only responsibility in accept-
ing or rejecting the reports shall be to determine, 
within the 180-day period, whether the studies fairly 
respond to the written request, have been conducted 
in accordance with commonly accepted scientific 
principles and protocols, and have been reported in 
accordance with the requirements of the Secretary 
for filing. 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00152
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
153 
‘‘(4) EFFECT OF SUBSECTION.—Nothing in this 
subsection alters or amends section 301(j) of this 
Act or section 552 of title 5 or section 1905 of title 
18, United States Code. 
‘‘(e) NOTICE OF DETERMINATIONS ON STUDIES RE-
QUIREMENT.— 
‘‘(1) IN GENERAL.—The Secretary shall publish 
a notice of any determination, made on or after the 
date of the enactment of the Best Pharmaceuticals 
for Children Act of 2007, that the requirements of 
subsection (d) have been met and that submissions 
and approvals under subsection (b)(2) or (j) of sec-
tion 505 for a drug will be subject to the provisions 
of this section. Such notice shall be published not 
later than 30 days after the date of the Secretary’s 
determination regarding market exclusivity and shall 
include a copy of the written request made under 
subsection (b) or (c). 
‘‘(2) IDENTIFICATION
OF
CERTAIN
DRUGS.— 
The Secretary shall publish a notice identifying any 
drug for which, on or after the date of the enact-
ment of the Best Pharmaceuticals for Children Act 
of 2007, a pediatric formulation was developed, 
studied, and found to be safe and effective in the pe-
diatric population (or specified subpopulation) if the 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00153
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
154 
pediatric formulation for such drug is not introduced 
onto the market within one year after the date that 
the Secretary publishes the notice described in para-
graph (1). Such notice identifying such drug shall be 
published not later than 30 days after the date of 
the expiration of such one year period. 
‘‘(f) INTERNAL REVIEW
OF WRITTEN REQUESTS 
AND PEDIATRIC STUDIES.— 
‘‘(1) INTERNAL REVIEW.—The Secretary shall 
utilize the internal review committee established 
under section 505C to review all written requests 
issued on or after the date of the enactment of the 
Best Pharmaceuticals for Children Act of 2007, in 
accordance with paragraph (2). 
‘‘(2) REVIEW
OF
WRITTEN
REQUESTS.—The 
committee referred to in paragraph (1) shall review 
all written requests issued pursuant to this section 
prior to being issued. 
‘‘(3) REVIEW
OF
PEDIATRIC
STUDIES.—The 
committee referred to in paragraph (1) may review 
studies conducted pursuant to this section to make 
a recommendation to the Secretary whether to ac-
cept or reject such reports under subsection (d)(3). 
‘‘(4) ACTIVITY BY COMMITTEE.—The committee 
referred to in paragraph (1) may operate using ap-
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00154
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
155 
propriate members of such committee and need not 
convene all members of the committee. 
‘‘(5) DOCUMENTATION
OF
COMMITTEE
AC-
TION.—For each drug, the committee referred to in 
paragraph (1) shall document, for each activity de-
scribed in paragraph (2) or (3), which members of 
the committee participated in such activity. 
‘‘(6) TRACKING PEDIATRIC STUDIES AND LA-
BELING CHANGES.—The Secretary, in consultation 
with the committee referred to in paragraph (1), 
shall track and make available to the public, in an 
easily accessible manner, including through posting 
on the Web site of the Food and Drug Administra-
tion— 
‘‘(A) the number of studies conducted 
under this section and under section 409I of 
the Public Health Service Act; 
‘‘(B) the specific drugs and drug uses, in-
cluding labeled and off-labeled indications, stud-
ied under such sections; 
‘‘(C) the types of studies conducted under 
such sections, including trial design, the num-
ber of pediatric patients studied, and the num-
ber of centers and countries involved; 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00155
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
156 
‘‘(D) the number of pediatric formulations 
developed and the number of pediatric formula-
tions not developed and the reasons such for-
mulations were not developed; 
‘‘(E) the labeling changes made as a result 
of studies conducted under such sections; 
‘‘(F) an annual summary of labeling 
changes made as a result of studies conducted 
under such sections for distribution pursuant to 
subsection (k)(2); and 
‘‘(G) information regarding reports sub-
mitted on or after the date of the enactment of 
the Best Pharmaceuticals for Children Act of 
2007. 
‘‘(g) 
LIMITATIONS.—Notwithstanding 
subsection 
(c)(2), a drug to which the six-month period under sub-
section (b) or (c) has already been applied— 
‘‘(1) may receive an additional six-month period 
under subsection (c)(1)(A)(i)(II) for a supplemental 
application if all other requirements under this sec-
tion are satisfied, except that such drug may not re-
ceive any additional such period under subsection 
(c)(1)(B); and 
‘‘(2) may not receive any additional such period 
under subsection (c)(1)(A)(ii). 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00156
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
157 
‘‘(h) RELATIONSHIP TO PEDIATRIC RESEARCH RE-
QUIREMENTS.—Notwithstanding any other provision of 
law, if any pediatric study is required by a provision of 
law (including a regulation) other than this section and 
such study meets the completeness, timeliness, and other 
requirements of this section, such study shall be deemed 
to satisfy the requirement for market exclusivity pursuant 
to this section. 
‘‘(i) LABELING CHANGES.— 
‘‘(1) PRIORITY STATUS FOR PEDIATRIC APPLI-
CATIONS
AND
SUPPLEMENTS.—Any application or 
supplement to an application under section 505 pro-
posing a labeling change as a result of any pediatric 
study conducted pursuant to this section— 
‘‘(A) shall be considered to be a priority 
application or supplement; and 
‘‘(B) shall be subject to the performance 
goals established by the Commissioner for pri-
ority drugs. 
‘‘(2) DISPUTE RESOLUTION.— 
‘‘(A) REQUEST
FOR
LABELING
CHANGE 
AND FAILURE TO AGREE.—If, on or after the 
date of the enactment of the Best Pharma-
ceuticals for Children Act of 2007, the Commis-
sioner determines that the sponsor and the 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00157
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
159 
‘‘(C) CONSIDERATION
OF
RECOMMENDA-
TIONS.—The Commissioner shall consider the 
recommendations of the Pediatric Advisory 
Committee and, if appropriate, not later than 
30 days after receiving the recommendation, 
make a request to the sponsor of the applica-
tion to make any labeling change that the Com-
missioner determines to be appropriate. 
‘‘(D) MISBRANDING.—If the sponsor of the 
application, within 30 days after receiving a re-
quest under subparagraph (C), does not agree 
to make a labeling change requested by the 
Commissioner, the Commissioner may deem the 
drug that is the subject of the application to be 
misbranded. 
‘‘(E) NO EFFECT ON AUTHORITY.—Noth-
ing in this subsection limits the authority of the 
United States to bring an enforcement action 
under this Act when a drug lacks appropriate 
pediatric labeling. Neither course of action (the 
Pediatric Advisory Committee process or an en-
forcement action referred to in the preceding 
sentence) shall preclude, delay, or serve as the 
basis to stay the other course of action. 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00159
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
160 
‘‘(j) OTHER LABELING CHANGES.—If, on or after the 
date of the enactment of the Best Pharmaceuticals for 
Children Act of 2007, the Secretary determines that a pe-
diatric study conducted under this section does or does 
not demonstrate that the drug that is the subject of the 
study is safe and effective, including whether such study 
results are inconclusive, in pediatric populations or sub-
populations, the Secretary shall order the labeling of such 
product to include information about the results of the 
study and a statement of the Secretary’s determination. 
‘‘(k) DISSEMINATION
OF
PEDIATRIC
INFORMA-
TION.— 
‘‘(1) IN GENERAL.—Not later than 210 days 
after the date of submission of a report on a pedi-
atric study under this section, the Secretary shall 
make available to the public the medical, statistical, 
and clinical pharmacology reviews of pediatric stud-
ies conducted under subsection (b) or (c). 
‘‘(2) DISSEMINATION
OF
INFORMATION
RE-
GARDING
LABELING
CHANGES.—Beginning on the 
date of the enactment of the Best Pharmaceuticals 
for Children Act of 2007, the Secretary shall include 
as a requirement of a written request that the spon-
sors of the studies that result in labeling changes 
that are reflected in the annual summary developed 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00160
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
161 
pursuant to subsection (f)(3)(F) distribute, at least 
annually (or more frequently if the Secretary deter-
mines that it would be beneficial to the public 
health), such information to physicians and other 
health care providers. 
‘‘(3) EFFECT OF SUBSECTION.—Nothing in this 
subsection alters or amends section 301(j) of this 
Act or section 552 of title 5 or section 1905 of title 
18, United States Code. 
‘‘(l) ADVERSE EVENT REPORTING.— 
‘‘(1) REPORTING IN YEAR ONE.—Beginning on 
the date of the enactment of the Best Pharma-
ceuticals for Children Act of 2007, during the one- 
year period beginning on the date a labeling change 
is approved pursuant to subsection (i), the Secretary 
shall ensure that all adverse event reports that have 
been received for such drug (regardless of when such 
report was received) are referred to the Office of Pe-
diatric Therapeutics established under section 6 of 
the Best Pharmaceuticals for Children Act (Public 
Law 107–109). In considering the reports, the Di-
rector of such Office shall provide for the review of 
the reports by the Pediatric Advisory Committee, in-
cluding obtaining any recommendations of such 
Committee regarding whether the Secretary should 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00161
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
162 
take action under this Act in response to such re-
ports. 
‘‘(2) REPORTING IN SUBSEQUENT YEARS.—Fol-
lowing the one-year period described in paragraph 
(1), the Secretary shall, as appropriate, refer to the 
Office of Pediatric Therapeutics all pediatric adverse 
event reports for a drug for which a pediatric study 
was conducted under this section. In considering 
such reports, the Director of such Office may pro-
vide for the review of such reports by the Pediatric 
Advisory Committee, including obtaining any rec-
ommendation of such Committee regarding whether 
the Secretary should take action in response to such 
reports. 
‘‘(3) EFFECT.—The requirements of this sub-
section shall supplement, not supplant, other review 
of such adverse event reports by the Secretary. 
‘‘(m) CLARIFICATION OF INTERACTION OF MARKET 
EXCLUSIVITY UNDER THIS SECTION AND MARKET EX-
CLUSIVITY AWARDED TO AN APPLICANT FOR APPROVAL 
OF A DRUG UNDER SECTION 505(j).—If a 180-day period 
under section 505(j)(5)(B)(iv) overlaps with a 6-month ex-
clusivity period under this section, so that the applicant 
for approval of a drug under section 505(j) entitled to the 
180-day period under that section loses a portion of the 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00162
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
163 
180-day period to which the applicant is entitled for the 
drug, the 180-day period shall be extended from— 
‘‘(1) the date on which the 180-day period 
would have expired by the number of days of the 
overlap, if the 180-day period would, but for the ap-
plication of this subsection, expire after the 6-month 
exclusivity period; or 
‘‘(2) the date on which the 6-month exclusivity 
period expires, by the number of days of the overlap 
if the 180-day period would, but for the application 
of this subsection, expire during the six-month exclu-
sivity period. 
‘‘(n) REFERRAL IF PEDIATRIC STUDIES NOT COM-
PLETED.— 
‘‘(1) IN GENERAL.—Beginning on the date of 
the enactment of the Best Pharmaceuticals for Chil-
dren Act of 2007, if pediatric studies of a drug have 
not been completed under subsection (d) and if the 
Secretary, through the committee established under 
section 505C, determines that there is a continuing 
need for information relating to the use of the drug 
in the pediatric population (including neonates, as 
appropriate), the Secretary shall carry out the fol-
lowing: 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00163
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
164 
‘‘(A) For a drug for which a listed patent 
has not expired, make a determination regard-
ing whether an assessment shall be required to 
be submitted under section 505B(b). Prior to 
making such a determination, the Secretary 
may not take more than 30 days to certify 
whether the Foundation for the National Insti-
tutes of Health has sufficient funding at the 
time of such certification to initiate and fund 
all of the studies in the written request in their 
entirety within the timeframes specified within 
the written request. Only if the Secretary 
makes such certification in the affirmative, the 
Secretary shall refer all pediatric studies in the 
written request to the Foundation for the Na-
tional Institutes of Health for the conduct of 
such studies, and such Foundation shall fund 
such studies. If no certification has been made 
at the end of the 30-day period, or if the Sec-
retary certifies that funds are not sufficient to 
initiate and fund all the studies in their en-
tirety, the Secretary shall consider whether as-
sessments shall be required under section 
505B(b) for such drug. 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00164
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
165 
‘‘(B) For a drug that has no listed patents 
or has 1 or more listed patents that have ex-
pired, the Secretary shall refer the drug for in-
clusion on the list established under section 
409I of the Public Health Service Act for the 
conduct of studies. 
‘‘(2) PUBLIC NOTICE.—The Secretary shall give 
the public notice of a decision under paragraph 
(1)(A) not to require an assessment under section 
505B and the basis for such decision. 
‘‘(3) EFFECT OF SUBSECTION.—Nothing in this 
subsection alters or amends section 301(j) of this 
Act or section 552 of title 5 or section 1905 of title 
18, United States Code. 
‘‘(o) PROMPT APPROVAL OF DRUGS UNDER SECTION 
505(j) WHEN PEDIATRIC INFORMATION IS ADDED TO LA-
BELING.— 
‘‘(1) GENERAL RULE.—A drug for which an ap-
plication has been submitted or approved under sec-
tion 505(j) shall not be considered ineligible for ap-
proval under that section or misbranded under sec-
tion 502 on the basis that the labeling of the drug 
omits a pediatric indication or any other aspect of 
labeling pertaining to pediatric use when the omitted 
indication or other aspect is protected by patent or 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00165
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
166 
by exclusivity under clause (iii) or (iv) of section 
505(j)(5)(F). 
‘‘(2) LABELING.—Notwithstanding clauses (iii) 
and (iv) of section 505(j)(5)(F), the Secretary may 
require that the labeling of a drug approved under 
section 505(j) that omits a pediatric indication or 
other aspect of labeling as described in paragraph 
(1) include— 
‘‘(A) a statement that, because of mar-
keting exclusivity for a manufacturer— 
‘‘(i) the drug is not labeled for pedi-
atric use; or 
‘‘(ii) in the case of a drug for which 
there is an additional pediatric use not re-
ferred to in paragraph (1), the drug is not 
labeled for the pediatric use under para-
graph (1); and 
‘‘(B) a statement of any appropriate pedi-
atric 
contraindications, 
warnings, 
or 
pre-
cautions that the Secretary considers necessary. 
‘‘(3) PRESERVATION
OF
PEDIATRIC
EXCLU-
SIVITY
AND
OTHER
PROVISIONS.—This subsection 
does not affect— 
‘‘(A) the availability or scope of exclusivity 
under this section; 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00166
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
167 
‘‘(B) the availability or scope of exclusivity 
under section 505 for pediatric formulations; 
‘‘(C) the question of the eligibility for ap-
proval of any application under section 505(j) 
that omits any other conditions of approval en-
titled to exclusivity under clause (iii) or (iv) of 
section 505(j)(5)(F); or 
‘‘(D) except as expressly provided in para-
graphs (1) and (2), the operation of section 
505. 
‘‘(p) INSTITUTE OF MEDICINE STUDY.—Not later 
than 3 years after the date of the enactment of the Best 
Pharmaceuticals for Children Act of 2007, the Secretary 
shall enter into a contract with the Institute of Medicine 
to conduct a study and report to Congress regarding the 
written requests made and the studies conducted pursuant 
to this section. The Institute of Medicine may devise an 
appropriate mechanism to review a representative sample 
of requests made and studies conducted pursuant to this 
section in order to conduct such study. Such study shall— 
‘‘(1) review such representative written requests 
issued by the Secretary since 1997 under sub-
sections (b) and (c); 
‘‘(2) review and assess such representative pedi-
atric studies conducted under subsections (b) and (c) 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00167
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
168 
since 1997 and labeling changes made as a result of 
such studies; 
‘‘(3) review the use of extrapolation for pedi-
atric subpopulations, the use of alternative endpoints 
for pediatric populations, neonatal assessment tools, 
and ethical issues in pediatric clinical trials; 
‘‘(4) review and assess the pediatric studies of 
biological products as required under subsections (a) 
and (b) of section 505B; and 
‘‘(5) make recommendations regarding appro-
priate incentives for encouraging pediatric studies of 
biologics. 
‘‘(q) SUNSET.—A drug may not receive any 6-month 
period under subsection (b) or (c) unless— 
‘‘(1) on or before October 1, 2012, the Sec-
retary makes a written request for pediatric studies 
of the drug; 
‘‘(2) on or before October 1, 2012, an applica-
tion for the drug is accepted for filing under section 
505(b); and 
‘‘(3) all requirements of this section are met.’’. 
(2) APPLICABILITY.— 
(A) IN GENERAL.—The amendment made 
by this subsection shall apply to written re-
quests under section 505A of the Federal Food, 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00168
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
169 
Drug, and Cosmetic Act (21 U.S.C. 355a) 
issued on or after the date of the enactment of 
this Act. 
(B) CERTAIN
WRITTEN
REQUESTS.—A 
written request issued under section 505A of 
the Federal Food, Drug, and Cosmetic Act, as 
in effect on the day before the date of the en-
actment of this Act, which has been accepted 
and for which no determination under sub-
section (d)(2) of such section has been made 
before such date of enactment, shall be subject 
to such section 505A, except that such written 
requests 
shall 
be 
subject 
to 
subsections 
(d)(2)(A)(ii), (e)(1) and (2), (f), (i)(2)(A), (j), 
(k)(1), ( l)(1), and (n) of section 505A of the 
Federal Food, Drug, and Cosmetic Act, as in 
effect on or after the date of the enactment of 
this Act. 
(b) PROGRAM FOR PEDIATRIC STUDIES OF DRUGS.— 
Section 409I of the Public Health Service Act (42 U.S.C. 
284m) is amended to read as follows: 
‘‘SEC. 409I. PROGRAM FOR PEDIATRIC STUDIES OF DRUGS. 
‘‘(a) LIST
OF
PRIORITY
ISSUES
IN
PEDIATRIC 
THERAPEUTICS.— 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00169
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
170 
‘‘(1) IN GENERAL.—Not later than one year 
after the date of the enactment of the Best Pharma-
ceuticals for Children Act of 2007, the Secretary, 
acting through the Director of the National Insti-
tutes of Health and in consultation with the Com-
missioner of Food and Drugs and experts in pedi-
atric research, shall develop and publish a priority 
list of needs in pediatric therapeutics, including 
drugs or indications that require study. The list 
shall be revised every three years. 
‘‘(2) CONSIDERATION OF AVAILABLE INFORMA-
TION.—In developing and prioritizing the list under 
paragraph (1), the Secretary shall consider— 
‘‘(A) therapeutic gaps in pediatrics that 
may 
include 
developmental 
pharmacology, 
pharmacogenetic determinants of drug re-
sponse, metabolism of drugs and biologics in 
children, and pediatric clinical trials; 
‘‘(B) particular pediatric diseases, dis-
orders or conditions where more complete 
knowledge and testing of therapeutics, including 
drugs and biologics, may be beneficial in pedi-
atric populations; and 
‘‘(C) the adequacy of necessary infrastruc-
ture to conduct pediatric pharmacological re-
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00170
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
171 
search, including research networks and trained 
pediatric investigators. 
‘‘(b) PEDIATRIC STUDIES
AND RESEARCH.—The 
Secretary, acting through the National Institutes of 
Health, shall award funds to entities that have the exper-
tise to conduct pediatric clinical trials or other research 
(including qualified universities, hospitals, laboratories, 
contract research organizations, practice groups, federally 
funded programs such as pediatric pharmacology research 
units, other public or private institutions, or individuals) 
to enable the entities to conduct the drug studies or other 
research on the issues described in subsection (a). The 
Secretary may use contracts, grants, or other appropriate 
funding mechanisms to award funds under this subsection. 
‘‘(c) PROCESS
FOR PROPOSED PEDIATRIC STUDY 
REQUESTS AND LABELING CHANGES.— 
‘‘(1) SUBMISSION
OF
PROPOSED
PEDIATRIC 
STUDY REQUEST.—The Director of the National In-
stitutes of Health shall, as appropriate, submit pro-
posed pediatric study requests for consideration by 
the Commissioner of Food and Drugs for pediatric 
studies of a specific pediatric indication identified 
under subsection (a). Such a proposed pediatric 
study request shall be made in a manner equivalent 
to a written request made under subsection (b) or 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00171
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
172 
(c) of section 505A of the Federal Food, Drug, and 
Cosmetic Act, including with respect to the informa-
tion provided on the pediatric studies to be con-
ducted pursuant to the request. The Director of the 
National Institutes of Health may submit a pro-
posed pediatric study request for a drug for which— 
‘‘(A)(i) there is an approved application 
under section 505(j) of the Federal Food, 
Drug, and Cosmetic Act; or 
‘‘(ii) there is a submitted application that 
could be approved under the criteria of such 
section; and 
‘‘(B) there is no patent protection or mar-
ket exclusivity protection for at least one form 
of the drug under the Federal Food, Drug, and 
Cosmetic Act; and 
‘‘(C) additional studies are needed to as-
sess the safety and effectiveness of the use of 
the drug in the pediatric population. 
‘‘(2) WRITTEN REQUEST TO HOLDERS OF AP-
PROVED APPLICATIONS FOR DRUGS LACKING EXCLU-
SIVITY.—The Commissioner of Food and Drugs, in 
consultation with the Director of the National Insti-
tutes of Health, may issue a written request based 
on the proposed pediatric study request for the indi-
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00172
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
173 
cation or indications submitted pursuant to para-
graph (1) (which shall include a timeframe for nego-
tiations for an agreement) for pediatric studies con-
cerning a drug identified under subsection (a) to all 
holders of an approved application for the drug 
under section 505 of the Federal Food, Drug, and 
Cosmetic Act. Such a written request shall be made 
in a manner equivalent to the manner in which a 
written request is made under subsection (b) or (c) 
of section 505A of such Act, including with respect 
to information provided on the pediatric studies to 
be conducted pursuant to the request and using ap-
propriate formulations for each age group for which 
the study is requested. 
‘‘(3) REQUESTS FOR PROPOSALS.—If the Com-
missioner of Food and Drugs does not receive a re-
sponse to a written request issued under paragraph 
(2) not later than 30 days after the date on which 
a request was issued, the Secretary, acting through 
the Director of the National Institutes of Health and 
in consultation with the Commissioner of Food and 
Drugs, shall publish a request for proposals to con-
duct the pediatric studies described in the written 
request in accordance with subsection (b). 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00173
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
174 
‘‘(4) DISQUALIFICATION.—A holder that re-
ceives a first right of refusal shall not be entitled to 
respond to a request for proposals under paragraph 
(3). 
‘‘(5) CONTRACTS, GRANTS, OR OTHER FUNDING 
MECHANISMS.—A contract, grant, or other funding 
may be awarded under this section only if a proposal 
is submitted to the Secretary in such form and man-
ner, and containing such agreements, assurances, 
and information as the Secretary determines to be 
necessary to carry out this section. 
‘‘(6) REPORTING OF STUDIES.— 
‘‘(A) IN
GENERAL.—On completion of a 
pediatric study in accordance with an award 
under this section, a report concerning the 
study shall be submitted to the Director of the 
National Institutes of Health and the Commis-
sioner of Food and Drugs. The report shall in-
clude all data generated in connection with the 
study, including a written request if issued. 
‘‘(B) AVAILABILITY
OF
REPORTS.—Each 
report submitted under subparagraph (A) shall 
be considered to be in the public domain (sub-
ject to section 505A(d)(4) of the Federal Food, 
Drug, and Cosmetic Act) and shall be assigned 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00174
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
175 
a docket number by the Commissioner of Food 
and Drugs. An interested person may submit 
written comments concerning such pediatric 
studies to the Commissioner of Food and 
Drugs, and the written comments shall become 
part of the docket file with respect to each of 
the drugs. 
‘‘(C) ACTION
BY
COMMISSIONER.—The 
Commissioner of Food and Drugs shall take ap-
propriate action in response to the reports sub-
mitted under subparagraph (A) in accordance 
with paragraph (7). 
‘‘(7) REQUESTS FOR LABELING CHANGE.—Dur-
ing the 180-day period after the date on which a re-
port is submitted under paragraph (6)(A), the Com-
missioner of Food and Drugs shall— 
‘‘(A) review the report and such other data 
as are available concerning the safe and effec-
tive use in the pediatric population of the drug 
studied; 
‘‘(B) negotiate with the holders of ap-
proved applications for the drug studied for any 
labeling changes that the Commissioner of Food 
and Drugs determines to be appropriate and re-
quests the holders to make; and 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00175
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
176 
‘‘(C)(i) place in the public docket file a 
copy of the report and of any requested labeling 
changes; and 
‘‘(ii) publish in the Federal Register and 
through a posting on the Web site of the Food 
and Drug Administration a summary of the re-
port and a copy of any requested labeling 
changes. 
‘‘(8) DISPUTE RESOLUTION.— 
‘‘(A) REFERRAL TO PEDIATRIC ADVISORY 
COMMITTEE.—If, not later than the end of the 
180-day period specified in paragraph (7), the 
holder of an approved application for the drug 
involved does not agree to any labeling change 
requested by the Commissioner of Food and 
Drugs under that paragraph, the Commissioner 
of Food and Drugs shall refer the request to 
the Pediatric Advisory Committee. 
‘‘(B) ACTION BY THE PEDIATRIC ADVISORY 
COMMITTEE.—Not later than 90 days after re-
ceiving a referral under subparagraph (A), the 
Pediatric Advisory Committee shall— 
‘‘(i) review the available information 
on the safe and effective use of the drug 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00176
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
178 
lacks appropriate pediatric labeling. Neither course 
of action (the Pediatric Advisory Committee process 
or an enforcement action referred to in the pre-
ceding sentence) shall preclude, delay, or serve as 
the basis to stay the other course of action. 
‘‘(d) DISSEMINATION
OF
PEDIATRIC
INFORMA-
TION.—Not later than one year after the date of the enact-
ment of the Best Pharmaceuticals for Children Act of 
2007, the Secretary, acting through the Director of the 
National Institutes of Health, shall study the feasibility 
of establishing a compilation of information on pediatric 
drug use and report the findings to Congress. 
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.— 
‘‘(1) IN GENERAL.—There are authorized to be 
appropriated to carry out this section— 
‘‘(A) $200,000,000 for fiscal year 2008; 
and 
‘‘(B) such sums as are necessary for each 
of the four succeeding fiscal years. 
‘‘(2) AVAILABILITY.—Any amount appropriated 
under paragraph (1) shall remain available to carry 
out this section until expended.’’. 
(c) FOUNDATION FOR THE NATIONAL INSTITUTES 
OF HEALTH.—Section 499(c)(1)(C) of the Public Health 
Service Act (42 U.S.C. 290b(c)(1)(C)) is amended by 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00178
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
179 
striking ‘‘and studies listed by the Secretary pursuant to 
section 409I(a)(1)(A) of this Act and referred under sec-
tion 505A(d)(4)(C) of the Federal Food, Drug and Cos-
metic Act (21 U.S.C. 355(a)(d)(4)(C)’ ’’ and inserting 
‘‘and studies for which the Secretary issues a certification 
in the affirmative under section 505A(n)(1)(A) of the Fed-
eral Food, Drug, and Cosmetic Act’’. 
(d) CONTINUATION
OF
OPERATION
OF
COM-
MITTEE.—Section 14 of the Best Pharmaceuticals for 
Children Act (42 U.S.C. 284m note) is amended by adding 
at the end the following new subsection: 
‘‘(d) CONTINUATION
OF
OPERATION
OF
COM-
MITTEE.—Notwithstanding section 14 of the Federal Ad-
visory Committee Act, the advisory committee shall con-
tinue to operate during the five-year period beginning on 
the date of the enactment of the Best Pharmaceuticals for 
Children Act of 2007.’’. 
(e) PEDIATRIC SUBCOMMITTEE OF THE ONCOLOGIC 
DRUGS ADVISORY COMMITTEE.—Section 15 of the Best 
Pharmaceuticals for Children Act (42 U.S.C. 284m note) 
is amended— 
(1) in subsection (a)— 
(A) in paragraph (1)— 
(i) in subparagraph (B), by striking 
‘‘and’’ after the semicolon; 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00179
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
180 
(ii) in subparagraph (C), by striking 
the period at the end and inserting ‘‘; 
and’’; and 
(iii) by adding at the end the fol-
lowing new subparagraph: 
‘‘(D) provide recommendations to the in-
ternal review committee created under section 
505B(f) of the Federal Food, Drug, and Cos-
metic Act regarding the implementation of 
amendments to sections 505A and 505B of the 
Federal Food, Drug, and Cosmetic Act with re-
spect to the treatment of pediatric cancers.’’; 
and 
(B) by adding at the end the following new 
paragraph: 
‘‘(3) CONTINUATION OF OPERATION OF SUB-
COMMITTEE.—Notwithstanding section 14 of the 
Federal Advisory Committee Act, the Subcommittee 
shall continue to operate during the five-year period 
beginning on the date of the enactment of the Best 
Pharmaceuticals for Children Act of 2007.’’; and 
(2) in subsection (d), by striking ‘‘2003’’ and 
inserting ‘‘2009’’. 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00180
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
181 
(f) EFFECTIVE DATE AND LIMITATION FOR RULE 
RELATING
TO
TOLL-FREE
NUMBER
FOR
ADVERSE 
EVENTS ON LABELING FOR HUMAN DRUG PRODUCTS.— 
(1) IN GENERAL.—Notwithstanding subchapter 
II of chapter 5, and chapter 7, of title 5, United 
States Code (commonly known as the ‘‘Administra-
tive Procedure Act’’) and any other provision of law, 
the proposed rule issued by the Commissioner of 
Food and Drugs entitled ‘‘Toll-Free Number for Re-
porting Adverse Events on Labeling for Human 
Drug Products,’’ 69 Fed. Reg. 21778, (April 22, 
2004) shall take effect on January 1, 2008, unless 
such Commissioner issues the final rule before such 
date. 
(2) LIMITATION.—The proposed rule that takes 
effect under subsection (a), or the final rule de-
scribed under subsection (a), shall, notwithstanding 
section 17(a) of the Best Pharmaceuticals for Chil-
dren Act (21 U.S.C. 355b(a)), not apply to a drug— 
(A) for which an application is approved 
under section 505 of the Federal Food, Drug, 
and Cosmetic Act (21 U.S.C. 355); 
(B) that is not described under section 
503(b)(1) of such Act (21 U.S.C. 353(b)(1)); 
and 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00181
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
182 
(C) the packaging of which includes a toll- 
free number through which consumers can re-
port complaints to the manufacturer or dis-
tributor of the drug. 
SEC. 503. TRAINING OF PEDIATRIC PHARMACOLOGISTS. 
(a) INVESTMENT IN TOMORROW’S PEDIATRIC RE-
SEARCHERS.—Section 452G(2) of the Public Health Serv-
ice Act (42 U.S.C. 285g–10(2)) is amended by adding be-
fore the period at the end the following: ‘‘, including pedi-
atric pharmacological research’’. 
(b) PEDIATRIC RESEARCH LOAN REPAYMENT PRO-
GRAM.—Section 487F(a)(1) of the Public Health Service 
Act (42 U.S.C. 288–6(a)(1)) is amended by inserting ‘‘in-
cluding pediatric pharmacological research,’’ after ‘‘pedi-
atric research,’’. 
TITLE VI—REAGAN-UDALL 
FOUNDATION 
SEC. 601. THE REAGAN-UDALL FOUNDATION FOR THE 
FOOD AND DRUG ADMINISTRATION. 
(a) IN GENERAL.—Chapter VII of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 371 et seq.) is amend-
ed by adding at the end the following: 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00182
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
183 
‘‘Subchapter I—Reagan-Udall Foundation for 
the Food and Drug Administration 
‘‘SEC. 770. ESTABLISHMENT AND FUNCTIONS OF THE FOUN-
DATION. 
‘‘(a) IN GENERAL.—A nonprofit corporation to be 
known as the Reagan-Udall Foundation for the Food and 
Drug Administration (referred to in this subchapter as the 
‘Foundation’) shall be established in accordance with this 
section. The Foundation shall be headed by an Executive 
Director, appointed by the members of the Board of Direc-
tors under subsection (e). The Foundation shall not be 
an agency or instrumentality of the United States Govern-
ment. 
‘‘(b) PURPOSE OF FOUNDATION.—The purpose of 
the Foundation is to advance the mission of the Food and 
Drug Administration to modernize medical, veterinary, 
food, food ingredient, and cosmetic product development, 
accelerate innovation, and enhance product safety. 
‘‘(c) DUTIES OF THE FOUNDATION.—The Founda-
tion shall— 
‘‘(1) taking into consideration the Critical Path 
reports and priorities published by the Food and 
Drug Administration, identify unmet needs in the 
development, manufacture, and evaluation of the 
safety and effectiveness, including postapproval, of 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00183
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
184 
devices, including diagnostics, biologics, and drugs, 
and the safety of food, food ingredients, and cos-
metics, and including the incorporation of more sen-
sitive and predictive tools and devices to measure 
safety; 
‘‘(2) establish goals and priorities in order to 
meet the unmet needs identified in paragraph (1); 
‘‘(3) in consultation with the Secretary, identify 
existing and proposed Federal intramural and extra-
mural research and development programs relating 
to the goals and priorities established under para-
graph (2), coordinate Foundation activities with 
such programs, and minimize Foundation duplica-
tion of existing efforts; 
‘‘(4) award grants to, or enter into contracts, 
memoranda of understanding, or cooperative agree-
ments with, scientists and entities, which may in-
clude the Food and Drug Administration, university 
consortia, public-private partnerships, institutions of 
higher education, entities described in section 
501(c)(3) of the Internal Revenue Code (and exempt 
from tax under section 501(a) of such Code), and 
industry, to efficiently and effectively advance the 
goals and priorities established under paragraph (2); 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00184
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
185 
‘‘(5) recruit meeting participants and hold or 
sponsor (in whole or in part) meetings as appro-
priate to further the goals and priorities established 
under paragraph (2); 
‘‘(6) release and publish information and data 
and, to the extent practicable, license, distribute, 
and release material, reagents, and techniques to 
maximize, promote, and coordinate the availability of 
such material, reagents, and techniques for use by 
the Food and Drug Administration, nonprofit orga-
nizations, and academic and industrial researchers 
to further the goals and priorities established under 
paragraph (2); 
‘‘(7) ensure that— 
‘‘(A) action is taken as necessary to obtain 
patents for inventions developed by the Founda-
tion or with funds from the Foundation; 
‘‘(B) action is taken as necessary to enable 
the licensing of inventions developed by the 
Foundation or with funds from the Foundation; 
and 
‘‘(C) executed licenses, memoranda of un-
derstanding, material transfer agreements, con-
tracts, and other such instruments, promote, to 
the maximum extent practicable, the broadest 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00185
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
186 
conversion to commercial and noncommercial 
applications of licensed and patented inventions 
of the Foundation to further the goals and pri-
orities established under paragraph (2); 
‘‘(8) provide objective clinical and scientific in-
formation to the Food and Drug Administration 
and, upon request, to other Federal agencies to as-
sist in agency determinations of how to ensure that 
regulatory policy accommodates scientific advances 
and meets the agency’s public health mission; 
‘‘(9) conduct annual assessments of the unmet 
needs identified in paragraph (1); and 
‘‘(10) carry out such other activities consistent 
with the purposes of the Foundation as the Board 
determines appropriate. 
‘‘(d) BOARD OF DIRECTORS.— 
‘‘(1) ESTABLISHMENT.— 
‘‘(A) IN GENERAL.—The Foundation shall 
have a Board of Directors (referred to in this 
subchapter as the ‘Board’), which shall be com-
posed of ex officio and appointed members in 
accordance with this subsection. All appointed 
members of the Board shall be voting members. 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00186
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
187 
‘‘(B) EX OFFICIO MEMBERS.—The ex offi-
cio members of the Board shall be the following 
individuals or their designees: 
‘‘(i) The Commissioner. 
‘‘(ii) The Director of the National In-
stitutes of Health. 
‘‘(iii) The Director of the Centers for 
Disease Control and Prevention. 
‘‘(iv) The Director of the Agency for 
Healthcare Research and Quality. 
‘‘(C) APPOINTED MEMBERS.— 
‘‘(i) IN
GENERAL.—The ex officio 
members of the Board under subparagraph 
(B) shall, by majority vote, appoint to the 
Board 14 individuals, of which 9 shall be 
from a list of candidates to be provided by 
the National Academy of Sciences and 5 
shall be from lists of candidates provided 
by patient and consumer advocacy groups, 
professional scientific and medical soci-
eties, and industry trade organizations. Of 
such appointed members— 
‘‘(I) 4 shall be representatives of 
the general pharmaceutical, device, 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00187
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
188 
food, cosmetic, and biotechnology in-
dustries; 
‘‘(II) 3 shall be representatives of 
academic research organizations; 
‘‘(III) 2 shall be representatives 
of patient or consumer advocacy orga-
nizations; 
‘‘(IV) 1 shall be a representative 
of health care providers; and 
‘‘(V) 4 shall be at-large members 
with expertise or experience relevant 
to the purpose of the Foundation. 
‘‘(ii) REQUIREMENTS.— 
‘‘(I) EXPERTISE.—The ex officio 
members shall ensure the Board mem-
bership includes individuals with ex-
pertise in areas including the sciences 
of developing, manufacturing, and 
evaluating the safety and effectiveness 
of devices, including diagnostics, bio-
logics, and drugs, and the safety of 
food, food ingredients, and cosmetics. 
‘‘(II) FEDERAL
EMPLOYEES.— 
No employee of the Federal Govern-
ment shall be appointed as a member 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00188
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
189 
of the Board under this subparagraph 
or under paragraph (3)(B). 
‘‘(D) INITIAL MEETING.— 
‘‘(i) IN GENERAL.—Not later than 30 
days after the date of the enactment of 
this subchapter, the Secretary shall con-
vene a meeting of the ex officio members 
of the Board to— 
‘‘(I) incorporate the Foundation; 
and 
‘‘(II) appoint the members of the 
Board in accordance with subpara-
graph (C). 
‘‘(ii) SERVICE OF EX OFFICIO MEM-
BERS.—Upon the appointment of the 
members of the Board under clause 
(i)(II)— 
‘‘(I) the terms of service of the 
Director of the Centers for Disease 
Control and Prevention and of the Di-
rector of the Agency for Healthcare 
Research and Quality as ex officio 
members of the Board shall termi-
nate; and 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00189
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
193 
‘‘(B) prioritize and provide overall direc-
tion to the activities of the Foundation; 
‘‘(C) evaluate the performance of the Exec-
utive Director; and 
‘‘(D) carry out any other necessary activi-
ties regarding the functioning of the Founda-
tion. 
‘‘(3) TERMS AND VACANCIES.— 
‘‘(A) TERM.—The term of office of each 
member of the Board appointed under para-
graph (1)(C) shall be 4 years, except that the 
terms of offices for the initial appointed mem-
bers of the Board shall expire on a staggered 
basis as determined by the ex officio members. 
‘‘(B) VACANCY.—Any vacancy in the mem-
bership of the Board— 
‘‘(i) shall not affect the power of the 
remaining members to execute the duties 
of the Board; and 
‘‘(ii) shall be filled by appointment by 
the appointed members described in para-
graph (1)(C) by majority vote. 
‘‘(C) PARTIAL TERM.—If a member of the 
Board does not serve the full term applicable 
under subparagraph (A), the individual ap-
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00193
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
194 
pointed under subparagraph (B) to fill the re-
sulting vacancy shall be appointed for the re-
mainder of the term of the predecessor of the 
individual. 
‘‘(D) SERVING PAST TERM.—A member of 
the Board may continue to serve after the expi-
ration of the term of the member until a suc-
cessor is appointed. 
‘‘(4) COMPENSATION.—Members of the Board 
may not receive compensation for service on the 
Board. Such members may be reimbursed for travel, 
subsistence, and other necessary expenses incurred 
in carrying out the duties of the Board, as set forth 
in the bylaws issued by the Board. 
‘‘(e) INCORPORATION.—The ex officio members of the 
Board shall serve as incorporators and shall take whatever 
actions necessary to incorporate the Foundation. 
‘‘(f) NONPROFIT STATUS.—In carrying out sub-
section (b), the Board shall establish such policies and by-
laws under subsection (d), and the Executive Director 
shall carry out such activities under subsection (g), as may 
be necessary to ensure that the Foundation maintains sta-
tus as an organization that— 
‘‘(1) is described in subsection (c)(3) of section 
501 of the Internal Revenue Code of 1986; and 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00194
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
195 
‘‘(2) is, under subsection (a) of such section, ex-
empt from taxation. 
‘‘(g) EXECUTIVE DIRECTOR.— 
‘‘(1) IN GENERAL.—The Board shall appoint an 
Executive Director who shall serve at the pleasure of 
the Board. The Executive Director shall be respon-
sible for the day-to-day operations of the Foundation 
and shall have such specific duties and responsibil-
ities as the Board shall prescribe. 
‘‘(2) COMPENSATION.—The compensation of 
the Executive Director shall be fixed by the Board 
but shall not be greater than the compensation of 
the Commissioner. 
‘‘(h) ADMINISTRATIVE POWERS.—In carrying out 
this subchapter, the Board, acting through the Executive 
Director, may— 
‘‘(1) adopt, alter, and use a corporate seal, 
which shall be judicially noticed; 
‘‘(2) hire, promote, compensate, and discharge 
1 or more officers, employees, and agents, as may be 
necessary, and define their duties; 
‘‘(3) prescribe the manner in which— 
‘‘(A) real or personal property of the 
Foundation is acquired, held, and transferred; 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00195
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
196 
‘‘(B) general operations of the Foundation 
are to be conducted; and 
‘‘(C) the privileges granted to the Board 
by law are exercised and enjoyed; 
‘‘(4) with the consent of the applicable executive 
department or independent agency, use the informa-
tion, services, and facilities of such department or 
agencies in carrying out this section; 
‘‘(5) enter into contracts with public and pri-
vate organizations for the writing, editing, printing, 
and publishing of books and other material; 
‘‘(6) hold, administer, invest, and spend any 
gift, devise, or bequest of real or personal property 
made to the Foundation under subsection (i); 
‘‘(7) enter into such other contracts, leases, co-
operative agreements, and other transactions as the 
Board considers appropriate to conduct the activities 
of the Foundation; 
‘‘(8) modify or consent to the modification of 
any contract or agreement to which it is a party or 
in which it has an interest under this subchapter; 
‘‘(9) take such action as may be necessary to 
obtain patents and licenses for devices and proce-
dures developed by the Foundation and its employ-
ees; 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00196
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS
197 
‘‘(10) sue and be sued in its corporate name, 
and complain and defend in courts of competent ju-
risdiction; 
‘‘(11) appoint other groups of advisors as may 
be determined necessary to carry out the functions 
of the Foundation; and 
‘‘(12) exercise other powers as set forth in this 
section, and such other incidental powers as are nec-
essary to carry out its powers, duties, and functions 
in accordance with this subchapter. 
‘‘(i) 
ACCEPTANCE
OF
FUNDS
FROM
OTHER 
SOURCES.—The Executive Director may solicit and accept 
on behalf of the Foundation, any funds, gifts, grants, de-
vises, or bequests of real or personal property made to the 
Foundation, including from private entities, for the pur-
poses of carrying out the duties of the Foundation. 
‘‘(j) SERVICE OF FEDERAL EMPLOYEES.—Federal 
Government employees may serve on committees advisory 
to the Foundation and otherwise cooperate with and assist 
the Foundation in carrying out its functions, so long as 
such employees do not direct or control Foundation activi-
ties. 
‘‘(k) DETAIL OF GOVERNMENT EMPLOYEES; FEL-
LOWSHIPS.— 
VerDate Aug 31 2005 
23:45 Sep 21, 2007
Jkt 059200
PO 00000
Frm 00197
Fmt 6652
Sfmt 6201
E:\BILLS\H3580.CPH
H3580
bajohnson on PROD1PC69 with BILLS